SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (鈥淛unshi Biosciences鈥? HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (鈥淭ORCHLIGHT Study鈥? NCT04085276) examining the company鈥檚 product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.